This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Add Accuray Stock in Your Portfolio Now
by Zacks Equity Research
ARAY's solid product demand and revenue growth raise optimism about the stock.
Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength?
by Zacks Equity Research
AngioDynamics (ANGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
HealthEquity (HQY) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 9.86% and 3.84%, respectively, for the quarter ended October 2024. Do the numbers hold clues to what lies ahead for the stock?
ZYXI Stock Gains on the Completion of NiCO's Clinical Verification Trial
by Zacks Equity Research
Zynex announces the completion of the clinical verification trial of its NiCO pulse oximeter.
Veeva Systems Q3 Earnings & Revenues Beat, Operating Margin Up Y/Y
by Zacks Equity Research
VEEV's fiscal third-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.
Stryker Gains 30.2% Year to Date: What's Driving the Stock?
by Zacks Equity Research
SYK continues to witness growth on the back of a robust product line and strategic acquisitions.
GEHC Stock May Gain Following the Launches of Aurora and Clarify DL
by Zacks Equity Research
GE HealthCare announces that Aurora will expand the range of CT procedures and Clarify DL will enhance SPECT image quality.
GEHC Stock May Gain From Potential FDA Clearance for CleaRecon DL
by Zacks Equity Research
GE HealthCare announces the FDA submission of its CleaRecon DL technology to improve CBCT images.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL continues to witness growth on the back of its strong product portfolio.
NARI Stock Likely to Gain Following Reimbursement Approval in Japan
by Zacks Equity Research
Inari Medical announces reimbursement approval for ClotTriever Thrombectomy System in Japan and a new distribution partnership with Medikit.
GEHC Stock May Gain Following the Launch of Sonic DL for 3D Imaging
by Zacks Equity Research
GE HealthCare announces the new Sonic DL for 3D, which will reduce scan times and provide faster, high-quality imaging for the majority of MR scans.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
by Zacks Equity Research
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
MDT Stock May Gain Following the Positive Data From Optimize PRO Study
by Zacks Equity Research
Medtronic announces new positive data for its Evolut TAVR from the Optimize PRO clinical research.
Here's Why You Should Retain PDCO Stock in Your Portfolio for Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies on the back of its broad product line.
GEHC Stock May Gain Following the Launch of Pristina Via System
by Zacks Equity Research
GE HealthCare announces the Pristina Via mammography system, which will help minimize repetitive tasks and streamline workflows for mammography technologists.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL continues to gain from its strong segmental performance and improved operating margin.
STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
by Zacks Equity Research
Stereotaxis, in collaboration with MicroPort EP, announces the receipt of NMPA approval for its Genesis RMN System.
Reasons to Retain Intuitive Surgical Stock in Your Portfolio Now
by Zacks Equity Research
ISRG's strength in robotics continues to raise optimism among investors.
Will Ambry Genetics Acquisition Drive Tempus AI's Prospects?
by Zacks Equity Research
TEM acquires Ambry Genetics, expanding its testing portfolio and redefining precision medicine.
GEHC Stock May Gain on Its Enhanced OEC 3D Mobile CBCT C-Arm Portfolio
by Zacks Equity Research
GE HealthCare announces the latest application additions to its OEC 3D mobile CBCT C-arm portfolio to improve clinician workflow and visualization during endoscopic bronchoscopy procedures.
CAH Stock Gains on the Launch of Kendall SmartFlow Compression System
by Zacks Equity Research
Cardinal Health launches the next generation of the Kendall Compression Series, Kendall SCD SmartFlow Compression System, to aid pain relating to venous stasis.
DexCom and OURA Ink Partnership for Metabolic Health Innovation
by Zacks Equity Research
DXCM and smart ring maker, OURA, join forces to help individuals make informed decisions regarding diet, exercise and overall well-being.
Cencora Rallies 19.7% Year to Date: What's Driving the Stock?
by Zacks Equity Research
COR is gaining traction from the robust U.S. Healthcare Solutions segment, which raises optimism about the stock.
McKesson Stock Gains 34.1% YTD: What's Driving the Rally?
by Zacks Equity Research
MCK continues to gain because of robust segmental performance and raised fiscal 2025 guidance.
Veeva Stock May Gain on the Launch of GenAI Features in Vault CRM
by Zacks Equity Research
VEEV announces GenAI capabilities, CRM Bot and Voice Control, for its Vault CRM.